http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S61194020-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dfd617dc43a4c986d2dd81e4cb39d9dd |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate | 1985-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2d66afc02f6dc3e714a0cc9fd2f22e2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9b4c2489f438acd0e09a7219858174e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2e82468155cd16f32d5914fd9432291 |
| publicationDate | 1986-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-S61194020-A |
| titleOfInvention | Remedy for retinopathy |
| abstract | PURPOSE: To use 2-[2-phenyl-2-(2-pyridyl)]ethylamidazolin, or its acid addition salt well-known as a diabetic drug as a remedy for retinopathy by its improved inhibitory action on the whole blood aggregation. n CONSTITUTION: A remedy for retinopathy containing 2-[2-phenyl-2-(2- pyridyl)]ethylimidazolin, or its acid addition salt (this compound for short). The blood sugar lowering action and inhibitory action on blood platelet aggregation of this compound are well-known. The remedying effect of retinopathy accompanying diabetes is not directly linked to the inhibitory action of blood platelet aggregation, but greatly affected by inhibitory action on the whole blood aggregation. This compound shows improved inhibitory action on the whole blood aggregation, and is useful as a remedy for retinopathy. Dosage is usually performed by orally, and a dose is preferably 300W900mg/day. This compound has high safety. n COPYRIGHT: (C)1986,JPO&Japio |
| priorityDate | 1985-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226487001 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68864 |
Total number of triples: 23.